ViiV Healthcare Cabenuva (cabotegravir + rilpivirine) met the primary endpoint of the phase IIIb CROWN study, with superior six-month viral suppression versus standard oral ART in people with detectable HIV. The use is investigational and not approved.
GSK’s B7-H3-targeted ADC Ris-Rez cut the risk of death by 54% versus topotecan in the Phase III ARTEMIS-008 trial in relapsed small cell lung cancer in China, with a median overall survival of 18.5 months and fewer severe side effects than chemotherapy.
GSK’s Q2 2026 results show core operating profit up 7% to £2.8 billion, driven by Specialty Medicines and Vaccines, alongside plans for 20+ Phase III trial starts and the $10.6bn Nuvalent acquisition.
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review for non-small cell lung cancer.
The historic Utebzi FDA approval introduces the first and only oral carbapenem antibiotic for adult patients suffering from complicated urinary tract infections (cUTIs), offering an effective outpatient treatment pathway to combat multidrug-resistant pathogens.
GSK is set to demonstrate the strength of its oncology pipeline at major 2026 congresses, highlighting long-term outcomes for Jemperli and Blenrep alongside new GIST data.
GSK has finalized its $950 million acquisition of 35Pharma Inc., securing HS235 a potential best-in-class treatment for pulmonary hypertension with unique metabolic benefits.
GSK has reached a major milestone with the NMPA’s Exdensur depemokimab China approval. This ultra-long-acting biologic offers a breakthrough for severe asthma patients, requiring only two doses per year to maintain symptom control.
GSK has secured the Exdensur depemokimab China approval from the NMPA, introducing the first respiratory biologic with a twice-yearly dosing regimen for patients with severe eosinophilic asthma.
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data from the ARTEMIS-001 trial, this B7-H3-targeted antibody-drug conjugate aims to transform the prognosis for patients with extensive-stage disease, who currently face a median survival of just 8 months. This marks the sixth major global regulatory designation for risvutatug rezetecan, signaling its critical role in the future of oncology.
